Which Way Now For Mid-Sized European Pharmas?
Executive Summary
Compared with their top 20 European peers and with similarly sized companies in the US, many mid-sized European pharmas are struggling. IMS Health analyzes the predicament these companies find themselves in and outlines what they need to do to avoid being caught in an evolutionary backwater.
You may also be interested in...
Leo Pharma’s Global Ambitions In Hot Dermatology Space: Assembles New Top Team
The Danish company brings its heads of US, European and international businesses into the top management team to tackle the next stage of its development, targeting patients in new ways in the hot therapy area of dermatology.
Transforming A European Mid-Sized Pharma: An Interview With Almirall President Jorge Gallardo
Spain’s Almirall has taken a step back from the hypercompetitive respiratory market through its deal with AstraZeneca. It was becoming too expensive to compete in primary care against big pharma, says company President Jorge Gallardo. Almirall will use proceeds to chart a future course as a specialty pharma focused on dermatology.
Almirall Eyes Top Specialty Dermatology Role After its AstraZeneca Deal
Spain’s leading pharma company will use proceeds of its respiratory products sale to bulk up in dermatology, with the aim of becoming a global leader in the sector.